Vaginitides, STIs, PID Flashcards

1
Q

A 21 yo G0 LMP 1 week ago complains of a foul smelling, watery, slightly pruritic vaginal discharge for 3 weeks. She denies douching. She also states she does not use condoms with her male partner, with whom she has been having sex for about a month.

A

You diagnose your patient with bacterial vaginosis, and reassure her that this is not classified as a sexually transmitted infection. You prescribe metronidazole 500 mg PO BID x 1 week. She visits you two months later for a routine visit and tells you that the infection got much better very quickly.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

normal vaginal discharge in pts of reproductive age

A

-White, yellow or clear
-May change through menstrual cycle
-Nonpruritic
-Non-malodorous
-Not associated with any kind of pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

vaginal ecology

A

-reproductive age- pH of 3.5-4.5
-Lactobacillus spp. are produced in an estrogenized vagina
-Lactobacilli maintain this acidic pH by producing H2O2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MC vaginitides

A

-abnormal vaginal discharge:
-20-50% have bacterial vaginosis
-15-40% have vulvovaginal candidiasis

-5-35% have trichomoniasis
-Of these, only trichomoniasis is considered to be a sexually transmitted disease (STI)

-These can also coexist among each other, and/or with STIs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

prevalence and pathophysiology of bacterial vaginosis (BV)

A

-Prevalence: about 29.2% worldwide
-Due to an unknown event that changes the microbial flora of the vagina,
-Lactobacilli decline
-Facultative and strict anaerobes predominate

-Many associated organisms, including but not limited to:
-Atopobium vaginae
-Gardnerella vaginalis
-Bacteroides spp
-Mobiluncus spp
-Prevotella spp
-Porphyromonas spp

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

possible pathophysiology of BV: other etiologies

A

-An intravaginal event or exposure triggers the change in flora

-Vaginal exposure to:
-Semen
-Tampons
-Douching

-Could BV be an STI?
-Condoms seem to prevent BV
-Circumcision in male partners reduces incidence of BV in female partners by 40-60%
-Gardnerella vaginalis was thought to be a true pathogen in the past
-It is capable of forming a biofilm that can reduce the number of lactobacilli and that can increase BVAB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

hx of the pt with BV

A

-Length of symptoms
-History of similar episodes
-Sexual history- new partner?
-Use of sanitary products (douching, soaps, feminine hygiene)
-Relationship of symptoms to menses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

PE in BV and dx

A

-Thin, homogenous, gray to white discharge
-Fishy odor
-Pruritus
-Dysuria
-pt feels systemically well

-Dx:
-Amsel’s criteria:
-Thin, gray, homogenous vaginal D/C
-Presence of clue cells (>4 per HPF) seen on wet mount -> Clue cells: epithelial cells whose borders are obscured by adherent bacteria
-+KOH whiff test
-Vaginal pH>4.5!

-Gold standard: Gram stain with Nugent scoring
-DNA hybridization and detection of vaginal fluid sialidase are most common tests performed today
-Do not treat based only on Pap results suggesting BV

-tests for:
-Lactobacillus crispatus
-Lactobacillus jensenii
-Gardnerella vaginalis
-Atopobium vaginae
-BVAB-2
-Megasphera 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

BV tx

A

-Metronidazole
-Oral: !metronidazole 500 mg orally twice daily x 7 days; preferred initial therapy!
-Topical: metronidazole 0.75% vaginal gel, 1 applicator intravaginally once daily x 5 days

-Clindamycin
-Vaginal: clindamycin cream 2%, 1 applicator intravaginally at bedtime x 7 days

-Alternatives: (dont need to know)
-Secnidazole - 2 gm orally in a single dose
-Tinidazole- 2 gm orally once daily x 2 days, OR 1 gm orally once daily x 5 days
-Clindamycin- 300 mg orally twice daily x 7 days, OR Clindamycin ovules, 100 mg intravaginally once at bedtime x 3 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

BV sequelae

A

-Complications of pregnancy
-Prelabor rupture of membranes
-Premature prelabor rupture of membranes

-Complications of gynecologic surgery in which the vagina is entered
-Cellulitis or abscess formation

-HIV transmission to male partners

-Increased risk of infection with genital herpes, gonorrhea and chlamydia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

management of recurrent BV

A

-30% of pts treated for BV will have a recurrence within 1 month
-58% will have recurrence within 1 year
-Research indicates that G. vaginalis and other anaerobes form a biofilm that persists even after treatment

-Risk factors for recurrent BV:
-Douching
-Inability to restore lactobacilli to vaginal flora

-Regimen 1: metronidazole vaginal gel 0.75% 1 applicator intravaginally once daily x 10 days, then 2x/week x 6mo
-Regimen 2: Boric acid vaginal suppositories 600 mg intravaginally once daily at HS x 3 weeks AND simultaneously prescribe a standard regimen
-Regimen 3: metronidazole 2 gm orally and fluconazole 150 mg orally both administered monthly AFTER completion of a standard regimen

-In AFAB pts who have sex with AFAB people: Tx partner if sx
-In AFAB patients who have sex with AMAB people:
-Encourage condom use
-Consider circumcision
-No indication at present for treatment of AMAB people

-Evidence is mixed regarding the efficacy of probiotics
-Vaginal microbiome transplantation trials have demonstrated remission of intractable BV in a small group of patients -> More investigation is needed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

prevalence and patho of vulvovaginal candidiasis (VVC)

A

-70% of pts will ahve VVC at least once
-caused by overgrowth of Candida spp. often due to:
-Recent antibiotic use
-Pregnancy
-Hormonal contraceptive use
-Uncontrolled diabetes mellitus
-Sexual activity
-HIV infection
-Steroid use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Candida species responsible for VVC

A

-Candida albicans (>70%)
-Candida glabrata
-Candida guilliermondii
-Candida krusei
-Candida parapsilosis
-Candida tropicalis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

hx of pt with VVC

A

-intense pruritus of vulva and vagina
-white curdlike discharge
-dysuria
-dyspareunia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

PE and Dx: vulvovaginal candidiasis

A

-White curdlike discharge
-Hyperemic vulvovaginal tissues
-Excoriations of vulva and vagina

-pruritus, dysuria, dyspareunia
-pH < 4.5

-Dx:
-!Should not be based on hx and PE alone
-Include one of the following:
-Microscopy with visualization of pseudohyphae, hyphae, or spores
-Laboratory data- Culture, DNA probe technology, or PCR testing
-Do not treat based alone on Pap smear that identified fungal organisms
-Do not treat presumptively without clinical evaluations

-Pseudohyphae of C. albicans seen on wet mount

-PCR: 97% sensitive, 93% specific for: Candida albicans, Candida tropicalis, Candida glabrata, Candida parapsilosis, Candida krusei

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

uncomplicated vs complicated VVC

A

-UNCOMPLICATED VVC:
-infrequent episodes
-mild-moderate sx or findings
-infection with candida albicans
-no hx of compromised immune system

-COMPLICATED VVC:
-4 or more episodes annually
-severe symtpoms
-infection with non-C. albicans organism
-hx of compromised immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

over the counter tx options for uncomplicated VVC

A

-Clotrimazole:
-1% cream, 5 gm intravaginally once daily x 7-14 days
-2% cream, 5 gm intravaginally once daily x 3 days

-Tioconazole 6.5% ointment, 5 gm intravaginally once

-miconazole creams:
-2% cream, 5 gm intravaginally once daily x 7 days
-4% cream, 5 gm intravaginally once daily x 3 days

-miconazole suppositories:
-100 mg, 1 suppository intravaginally at bedtime x 7 days
-200 mg, 1 suppository intravaginally at bedtime x 3 days
-1200 mg, 1 suppository intravaginally at bedtime x 1 day

-Topical OTC imidazoles are highly effective BUT approx 33% dx correctly with VVC
-Correct dx include BV, contact dermatitis, and trichomoniasis

-Pts may confuse OTC imidazole preparations with:
-Vaginal anti-itch preparations
-Homeopathic preparations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

prescription only tx for uncomplicated VVC

A

-Fluconazole 150 mg, 1 tablet orally x 1 dose
-Butoconazole 2% cream, 5 gm intravaginally once
-Terconazole 0.4% cream, 5 gm intravaginally at bedtime x 7 days
-Terconazole 0.8% cream, 5 gm intravaginally at bedtime x 3 days
-Terconazole 80 mg, 1 suppository intravaginally at bedtime x 3 days

-terconazole -> Candida glabrata

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

management of complicated VVC: current C. albicans infections

A

-RF:
-Immunosuppression
-Diabetes mellitus
-Antibiotic use
-Recurrent bacterial vaginosis

-At least 3 episodes in 12 month period
-Must be documented with lab data
-Culture is the preferred means of diagnosis -> Includes identification of Candida spp and sensitivities

-MC species:
-Candida glabrata
-Candida parapsilosis
-Candida tropicalis
-Candida lusitaniae
-Candida krusei
-Obtain culture for identification of species and sensitivities

-Fluconazole 150 mg, 1 tab orally every 72 hours x 3 doses, THEN
-Fluconazole 150 mg, 1 tab orally every week x 6 months -> 50% of pts relapse within 6mo of completion of suppressive therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

tx of complicated VVC: non-C. albicans VVC

A

-Boric acid 600 mg suppository, 1 intravaginally at bedtime, for a minimum of 14 days
-Caution pts about avoiding accidental exposure to children or animals
-Flucytosine 5 gm intravaginally at bedtime x 14 days (for C. glabrata)
-Current cost is estimated between $182-$2000 per day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

management of complicated VVC: severe sx

A

-marked by fissures, edema, erosion
-prolonged intravaginal agent like terconazole x 10-14 days, OR
-Oral fluconazole (150mg or 200mg) taken daily every 72 hours x 3 doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

prevalence and patho of trichomoniasis

A

-Approx 276 million cases worldwide annually
-About 3-5 million annual cases in the United States
-Caused by Trichomonas vaginalis, a flagellated protozoan
-A sexually transmitted infection (STI) -> Fomite transmission is theoretically possible but is generally unlikely
-Adherence of the organism to epithelial cells and parasite-mediated apoptosis results in lysis of the cell and erosion of the epithelium
-In the female lower genital tract, T. vaginalis may be able to persist due to the presence of iron due to menstrual blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

risk factors of trichomoniasis

A

-MC in young pts of reproductive age
-Risk factors include:
-Oral contraceptive use
-Low socioeconomic status
-Smoking
-Non-monogamous relationships

-One of the only STIs that causes more symptoms in AFAB patients than in AMAB people
-Asymptomatic in 25-50% of all cisgender women

24
Q

hx of pt with trichomoniasis

A

-vaginal pruritus
-vaginal pain
-dysuria
-dyspareunia
-frothy!!! vaginal discharge
-worsened infection with menses
-abdominopelvic pain in assoc with PID

25
PE and dx in trichomoniasis
-green to yellow, frothy discharge -Strawberry cervix in 2% of patients -Possible infection of the urethra or of Skene’s glands -Possible signs of pelvic inflammatory disease: -Cervical motion tenderness -Uterine tenderness -Adnexal tenderness -Dx: -Microscopy- Identification of motile!!! trichomonads on wet mount -> Sensitivity: 38-82% -Nuclear acid amplification testing (NAAT)- Equally sensitive when performed on cervical, vaginal or urine samples -> Sensitivity: 95.3-100%; specificity: 95.2-100% -Antigen detection testing- POC testing; results available in 10 mins -> Sensitivity: 88.3%; specificity: 98.8% -Culture- Requires special media that most labs do not possess -> Takes over 5 days for results
26
sequelae of trichomoniasis
-PID -infertility -preterm birth -HIV infection and transmission -cervical intraepithelial neoplasia (CIN)
27
management of trichomoniasis
-In US, only 2 5-nitroimidazole agents are approved for tx -Recommended regimen: -Metronidazole 500 mg orally twice daily x 7 days -Alternative regimen: -Tinidazole 2 gm orally x 1 dose -Test for other STIs! -> HIV, syphilis, gonorrhea, chlamydia -In NY, trichomoniasis is not a reportable infection
28
gonorrhea
-Neisseria gonorrhoeae -Gram negative diplococcus -Usually silent in AFAB pts -May cause cervicitis -purulent discharge, dyspareunia, BLQ abdominal pain -reportable infection -Dx: -Gold standard: culture -Nuclear acid amplification -DNA probe -Cannot be distinguished clinically from chlamydia -Tx: -If mucopurulent cervicitis is noted, treat empirically with: -Ceftriaxone 500 mg IM x 1 dose (or 1 gm IM if the patient weighs >150 kg) AND doxycycline 100 mg PO BID x 7 days -If gonorrhea is not suspected but is diagnosed by lab, treat with ceftriaxone 500 mg IM x 1 dose alone -Test for CT, syphilis, HIV -Treat partner(s) (or suggest treatment) -A reportable infection -Becoming resistant to quinolones, tetracyclines and cephalosporins
29
chlamydia
-Chlamydia trachomatis -Gram indeterminate, obligate intracellular pathogen -May be silent or may cause cervicitis with s/s identical to GC -Purulent discharge, dyspareunia, BLQ abdominal pain -Cannot be distinguished clinically from GC -Dx: -Nucleic acid amplification test (replacing culture as the gold standard) -Culture -Tx: -Treat empirically if cervicitis is suspected as noted above under gonorrhea -Ceftriaxone 500 mg IM x 1 dose; doxycycline 100 mg PO BID x 7 days -However, treatment for chlamydia is doxycycline 100 mg PO BID hours x 7 days -Test for GC, syphilis, HIV -Treat partner(s) (or suggest treatment) -> In NYS, may Rx partner(s) via expedited partner therapy -A reportable infection
30
syphilis
-Treponema pallidum, a spirochete -3 phases in natural hx: -Primary syphilis: painless ulcer with rolled borders at site of inoculation; usually lasts 1-2wks -> CHANCRE (may not know) -2ndary syphilis: maculopapular rash that does not spare the palms or soles, usually 1-2wks after resolution of chancre (contagious by touch) -Tertiary syphilis: multiple sx (gummatous lesions, aortic aneurysm, etc.) that may develop decades after initial infection -picture- gummatous lesion
31
MC STI
-MC STI- HPV -MC REPORTED- CHLAMYDIA
32
neurosyphilis
-May occur at any stage of ds -Sx: -AMS (acute or chronic) -CN dysfunction -Hearing or visual changes -Stroke -Meningitis -positive test from CSF with these sx is considered dx of neurosyphilis
33
dx of syphilis
-RPR (rapid plasma reagin)/VDRL (Venereal Disease Research Laboratory) -Same lab with 2 different names -Results are binary (positive or negative; also reports titer) -A fourfold change in titer (represents two dilutions) is considered significant in a patient with h/o syphilis -may represent reinfection if the patient has engaged in high risk behavior -RPR/VDRL is performed with with confirmatory treponemal testing -Fluorescent treponemal antibody (FTA) -Obtain VDRL of CSF if neurosyphilis is suspected -False positive results for RPR/VDRL: -Infection -Autoimmune disease -HIV infection -Pregnancy -Drug use -Advancing age
34
tx of syphilis
-Primary or secondary syphilis: -PCN G 2.4 million units IM x 1 dose -Tertiary syphilis with normal CSF examination: -PCN G 7.2 million units (2.4 million units IM weekly x 3 weeks) -Neurosyphilis: -aqueous crystalline PCN G 3-4 million units IV Q4H x 10-14 days
35
asymptomatic pts with syphilis identified through routine screening: latent syphilis
-early latent or late latent syphilis -EARLY: -4x increase in titer in a year -h/o primary or secondary syphilis S/S in the past year -h/o sex partner with primary, secondary or early latent syphilis in last year -Conversion in past year of RPR/treponemal testing -Treatment- PCN G 2.4 million units IM x 1 dose -LATE: -Exists in anyone whose findings or history as noted above is or are > 1 year ago, OR in a patient with unknown prior history of testing -Treatment: PCN G 2.4 million units IM weekly x 3 doses
36
herpes simplex virus involving the genitalia
-2 types to consider: 1 & 2 -Type 1 generally affects the mouth (“above the waist”) -Type 2 generally affects the anogenital area (“below the waist”) -However, Type 1 lesions can affect the anogenital area -Incidence: Approx 16% of adults (50 million individuals) have a history of HSV II infection -There is no cure for HSV -A lifelong infection -Outbreaks vary widely in frequency and severity
37
presentation of primary HSV
-Prodrome of fever, myalgias, etc. for few days -Hypersensitivity of anogenital area -Appearance of multiple vesicular lesions accompanied by pain -Lesions are unroofed and pain increases -Gradually, lesions heal -Dx: -Appearance of classic lesions -Many patients do not have the “classic” lesion -Lesions may appear as linear lesions resembling an abrasion -Viral culture or PCR -Viral culture may be falsely negative, especially as lesions heal -!!PCR is best option
38
HSV screening
-Antibody (serology) testing -High sensitivity but may be falsely positive -IgM not considered useful as it may be positive during an outbreak -Do not screen routinely for HSV -Best to use PCR rather than antibody testing if one must screen
39
HSV tx
-Primary episode: -Must start within 72 hrs of presentation for maximum benefit -Will attenuate and shorten course of outbreak -Acyclovir 400 mg PO Q8H x 7-10 days -Acyclovir 200 mg PO Q4H x 5 doses x 7-10 days -Valacyclovir 1 gm PO Q12H x 7-10 days -Famciclovir 250 mg PO Q8H x 7-10 days -Episodic tx of recurrence of HSV: -Acyclovir or -Famciclovir or -Valacyclovir -if pt is having 3-4 episodes a year -Suppressive therapy: -Generally indicated in patients having >9 episodes/year with HSV-2 -Acyclovir 400 mg PO Q12H -Valacyclovir 500 mg PO Q12H -Valacyclovir 1 gm PO daily -Famciclovir 250 mg PO Q12H -HSV-1 infections tend to decrease in frequency after the first year -Suppressive therapy may be used in pts with frequent outbreaks after consideration of risks, benefits and alternatives
40
HSV counseling
-dx can be devastating -These patients need a great deal of support -May believe that sex life is over -May be profoundly depressed, even suicidal -Perceive great difficulty in finding a partner -May believe that they cannot reproduce -Offer counseling, support groups -Advise the patient to avoid sex during prodrome, outbreak -Condoms are helpful but not 100% effective
41
HPV
-MC STI -Virtually every human being who has ever been sexually active has been exposed to HPV -The overwhelming majority clear the infection within several years without any effect on the patient’s health -Discussion of HPV and its role in cervical carcinoma will be discussed elsewhere in the semester -Prevention: -Nonavalent HPV vaccine (Gardasil-9) from age 9 years on -2 doses (at 0 and 6-12 month intervals) if series is begun before 15th birthday -3 doses (at 0, 1-2, and 6 month intervals) if series is begun thereafter, or if the patient is immuncompromised -Catch-up immunization for patients not previously immunized up to age 26 -Discussion with unimmunized patients between 26-45 years about possible vaccination
42
genital warts
->90% are caused by HPV types 6 & 11 -5% of all cancers come from HPV -most will not cause any long-lasting problem except for cosmesis -may be treated in a variety of ways, depending on location and size -Dx: -Usually made clinically -May bx if: -The dx is uncertain -The condition does not resolve with treatment -The condition worsens -pic- right is neoplasia
43
tx of condylomata acuminata
-May observe, since most will resolve within 1 year -May use: -Podophyllin (Podofilox®) gel or solution -An antimitotic agent that causes necrosis of warts -Applied by patient 2x/day x 3 days, then 4 days off for up to 4 cycles for patients with total wart area <10 cm2 -Not to be used during pregnancy -Sinecatechins 15% ointment -A green tea extract -Patient applies 0.5 cm strand of ointment to each lesion 3x/day until resolution for up to 16 weeks -Avoid genital, sexual and oral contact while ointment is present -Immune modulators -!Imiquimod (Aldara) 3.75% or 5% cream -> 3x/wk for up to 16 weeks -> Wash area 6-10 hours after application -Cryotherapy - Logistically difficult -Cautery -Sharp dissection -Laser fulguration- Protect larynges of staff during fulguration by use of specialized masks and proper evacuation of vapor
44
counseling for genital warts
-Does not affect fertility in either partner -Condoms can protect partner to some degree but nothing is 100% effective -Warts rarely become malignant
45
PID
-lower genital tract infection that ascends from cervix or vagina to upper genital tract to involve the EM, tubes, ovaries, and sometimes the peritoneal cavity -most severe form of an STI in women -MC involves GC/CT -only 50% of pts have + test for either GC or CT -A polymicrobial event- Bacteroides, E. coli, Peptococcus, Streptococcus, Peptostreptococcus, Staphylococus, Actinomyces, others ->1 million cases annually in the US -Risk factors: -Younger age -Multiple partners -Prior h/o PID -Current or prior h/o STI, or partners with STI -H/O douching, BV -Use of oral contraceptives -Lower socioeconomic status
46
PID sx and dx
-abdominal pain -vaginal d/c -abnormal vaginal bleeding -N/V -fever -dyspareunia -Dx: -Treat for PID if: -abdominal pain -No other cause of the pain is identified -At least 1 of the following is present: -Uterine tenderness -Cervical motion tenderness -Adnexal tenderness -These also support dx: -WBCs on wet mount -Cervical exudate or friability -Fever >38.3o C -Elevated CRP, ESR -Evidence of +GC or +CT -Elaborate dx: -US with- tubo-ovarian abscess, hydrosalpinx, edematous tubes or tubal hyperemia -Endometrial bx -laparoscopy
47
PID ddx
-The abundance of differential diagnoses makes it very difficult to diagnose PID reliably -Ectopic or intrauterine pregnancy -UTI -Pyelonephritis -Appendicitis -Ovarian cyst or torsion -Endometriosis -Diverticulitis -Mesenteric adenitis -Leiomyomata uteri -Et cetera!
48
hydrosalpinx in PID
49
-TOA in PID
50
ancillary studies or consults that may be helpful: PID
-bHCG -CBC with differential -LFTs -GC, CT -T vaginalis -RPR -HIV Ab -Pelvic ultrasound -Endometrial biopsy -Wet mount -Surgical consult -ID consult
51
when to admit PID
-Dx is uncertain -pregnant -cannot tolerate oral medication -severely ill, has a high fever, and/or is septic -tubo-ovarian abscess -surgical emergency cannot be excluded -Inpt tx: -Ceftriaxone 1 gm IV every 24 hours AND -Doxycycline 100 mg PO Q12 hours AND -Metronidazole 500 mg orally or IV every 12 hours -Transition to oral regimen with doxycycline and metronidazole within 24-48 hours of clinical improvement -Patients should complete a total of 14 days of treatment (inpt and outpt)
52
PID outpt tx
-Ceftriaxone 500 mg IM x 1 dose AND -Doxycycline 100 mg PO Q12H x 14 days AND -Metronidazole 500 mg PO Q12H x 14 days
53
hydrosalpinx in PID
54
tubo-ovarian abscess
-A complication of pelvic inflammatory disease -An adnexal abscess forms -Requires surgical or IR drainage
55
-drainage of TOA via IR
56
PID f/u and complications
-should be examined (preferably by same examiner) within 72 hrs of initiation of antibiotic tx -If not improved, strongly consider admission, additional workup, and surgical management -Short-term sequelae -Tubo-ovarian abscess (see above) -May be managed via percutaneous drainage -May require TAH/BSO -Fitz-Hugh-Curtis syndrome (perihepatitis) -“Violin string” adhesions seen between liver and diaphragm -Secondary to chlamydial infection -Sepsis and, rarely, death -Long term sequelae -Infertility -Chronic pelvic pain -Ectopic pregnancy
57
fitz hugh curtis syndrome
-Adhesions between liver and diaphragm -“Violin strings” -Associated with PID caused by chlamydia -perihepatitis